K Pharma,Inc. (4896.T)
JPY 756.0
(-1.82%)
JPY 756.0
(-1.82%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 1 Billion | - | - |
| Cost of Revenue | 90 Million | - | 6.8 Million |
| Gross Profit | 910 Million | - | -6.8 Million |
| Operating Expenses | 543.94 Million | 353.77 Million | 219.49 Million |
| Selling, General and Administrative Expenses | -1000.00 | 169.38 Million | 67.97 Million |
| Research and Development Expenses | - | 163.97 Million | 134.51 Million |
| Other Expenses | 543.94 Million | -45 Thousand | -4000.00 |
| Cost and Expenses | 633.94 Million | 353.77 Million | 219.49 Million |
| Operating Income | 366.05 Million | -353.77 Million | -219.49 Million |
| Interest Expense | 11.84 Million | - | - |
| Income Tax Expense | 40.74 Million | 1.9 Million | -400 Thousand |
| Earnings before Tax | 301.07 Million | -390.52 Million | -229.11 Million |
| Net Income | 260.33 Million | -392.42 Million | -228.71 Million |
| Earnings Per Share Basic | 22.43 | -42.06 | -19.79 |
| Earnings Per Share Diluted | 22.43 | -42.06 | -19.79 |
| Weighted Average Shares Outstanding | 11.6 Million | 9.33 Million | 11.55 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.6 Million | 9.33 Million | 11.55 Million |
| Gross Margin | 0.91 | - | - |
| EBIT Margin | 0.37 | - | - |
| Profit Margin | 0.26 | - | - |
| EBITDA | 366.05 Million | -322.47 Million | -222.31 Million |
| Earnings Before Tax Margin | 0.37 | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1 Billion | - | - |
| Cost of Revenue | - | - | - | 90 Million | - | - |
| Gross Profit | - | - | - | 910 Million | - | - |
| Operating Expenses | 192.7 Million | 230.78 Million | 149.77 Million | 543.94 Million | 135.27 Million | 353.77 Million |
| Selling, General and Administrative Expenses | 104.51 Million | 82.18 Million | - | - | - | - |
| Research and Development Expenses | 88.18 Million | 148.6 Million | - | - | - | - |
| Other Expenses | 192.7 Million | - | -6.04 Million | -10.04 Million | - | -45 Thousand |
| Cost and Expenses | 192.7 Million | 230.78 Million | 149.77 Million | 633.94 Million | 135.27 Million | 353.77 Million |
| Operating Income | -192.7 Million | -230.78 Million | -149.77 Million | 366.05 Million | -135.27 Million | -353.77 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 578 Thousand | 579 Thousand | -33.11 Million | 40.74 Million | -25.89 Million | 1.9 Million |
| Earnings before Tax | -192.47 Million | -232.86 Million | -170.99 Million | 301.07 Million | -142.45 Million | -390.52 Million |
| Net Income | -193.05 Million | -233.44 Million | -137.88 Million | 260.33 Million | -116.55 Million | -392.42 Million |
| Earnings Per Share Basic | -16.64 | -20.12 | -14.78 | - | -10.04 | - |
| Earnings Per Share Diluted | -16.64 | -20.12 | -14.78 | - | -10.04 | - |
| Weighted Average Shares Outstanding | 11.6 Million | 11.6 Million | 9.33 Million | 11.6 Million | 11.6 Million | 9.33 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.6 Million | 11.6 Million | 9.33 Million | 11.6 Million | 11.6 Million | 9.33 Million |
| Gross Margin | - | - | - | 0.91 | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | 0.26 | - | - |
| EBITDA | -192.7 Million | -228.68 Million | -143.25 Million | - | -135.27 Million | - |
| Earnings Before Tax Margin | - | - | - | 0.37 | - | - |
R
NAGPI
AVCNF
INH
HERCULES
DFDS